Education, Science, Technology, Innovation and Life
Open Access
Sign In

Intervention of Bacterial Lysate in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Download as PDF

DOI: 10.23977/bactm.2022.020101 | Downloads: 13 | Views: 622


Yafei Qi 1, Weimin Zhang 1, Yinhuan Li 1


1 Pulmonary and Critical Care Medicine, Panyu Central Hospital, Guangzhou 511400, Guangdong, China

Corresponding Author

Yafei Qi


To study the performance of bacterial lysates in the treatment of acute exacerbation of chronic obstructive pulmonary disease(COPD). 60 patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) admitted in our hospital from November 2020 to June 2021 were prospectively studied. Divide them into two groups at random and received conventional treatment (conventional treatment group, n=30) and conventional treatment combined with bacterial lysate (bacterial lysate group, n=30) respectively. The treatment effect was assessed by the days of hospitalization, symptom scores, lung function, and the number of acute exacerbation readmissions within 6 months. The days of hospitalization was 6.77 (6,7) in the bacterial lysate group and 9.47 (8,10) in the control group, which was significantly lower in the bacterial lysate group than in the conventional treatment group (P=0.000). After treatment during hospitalization, procalcitonin decreased more significantly in the bacterial lysate group than in the conventional treatment group (P=0.024). After six months of treatment, the number of acute exacerbations was 0.90 (0,1) times in bacterial lysate group and 1.57 (1,2) times in conventional treatment group. During hospitalization, there was significant difference in 1-second forced expiratory volume (FEV1) and forced vital capacity (FVC) between the two groups and after 6-month follow-up (P=0.048, P=0.045). After 3 and 6 months of treatment, the scores of symptoms and signs in the bacterial lysate group were lower than those in the conventional treatment group. In the acute exacerbation of COPD, oral administration of bacterial lysates can reduce the number of exacerbations of COPD. shorten the days of hospitalization, improve the quality of life of patients, and delay the decline of lung function.


Bacterial Lysate, COPD, Immune, Acute Exacerbation


Yafei Qi, Weimin Zhang and Yinhuan Li, Intervention of Bacterial Lysate in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Bacteriology and Microbiology (2022) Vol. 2: 1-9. DOI:


[1] Singh, D, Agusti A, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J, 2019. 53(5).
[2] Lorenz J, Bals R, Dreher M, et al. Exacerbation of COPD. Pneumologie, 2017. 71(5): p. 269-289.
[3] Troiano, G., G. Messina, and N. Nante. Bacterial lysates (OM-85 BV): a cost-effective proposal in order to contrast antibiotic resistance. J Prev Med Hyg, 2021. 62(2): p. E564-E573.
[4] Ricci, R., Palmero C, Bazurro G, et al. The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes. Pulm Pharmacol Ther, 2014. 27(1): p. 109-13. 
[5] Rabin AS, Keyes CM, Oberg CL, et al. Emerging Interventional Pulmonary Therapies for Chronic Obstructive Pulmonary Disease. J Thorac Imaging, 2019. 34(4): p. 248-257.
[6] Wilkinson TM, Donaldson GC, Hurst JR, et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2004. 169(12): p. 1298-303.
[7] Avdeev, S.N., Nuralieva GS, Gainitdinova VV, et al. Clinical efficacy of mechanical bacterial lysate in the prevention of infectious exacerbations of chronic obstructive pulmonary disease. Ter Arkh, 2020. 92(4): p. 57-63.
[8] Lusuardi, M., Challenging mucosal immunity with bacterial extracts to prevent respiratory infections: an old therapy revisited. Monaldi Arch Chest Dis, 2004. 61(1): p. 4-5.
[9] Lusuardi M, Capelli A, Carli S, et al. Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis. Chest, 1993. 103(6): p. 1783-91.
[10] Koatz AM, Coe NA, Cicerán A, et al. Clinical and Immunological Benefits of OM-85 Bacterial Lysate in Patients with Allergic Rhinitis, Asthma, and COPD and Recurrent Respiratory Infections. Lung, 2016. 194(4): p. 687-97.
[11] Mauel J, Van Pham T, Kreis B, et al. Stimulation by a bacterial extract (Broncho-Vaxom) of the metabolic and functional activities of murine macrophages. Int J Immunopharmacol, 1989. 11(6): p. 637-45.
[12] Ritchie, A.I. and J.A. Wedzicha, Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. Clin Chest Med, 2020. 41(3): p. 421-438.
[13] Jing Li, Jinping Zheng, Jinping Yuan, et al. Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease. Chinese Medical Journal,2004(06):28-34. 
[14] Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax, 2006. 61(1): p. 23-8.
[15] Ni W, Bao J, Yang D, et al. Potential of serum procalcitonin in predicting bacterial exacerbation and guiding antibiotic administration in severe COPD exacerbations: a systematic review and meta-analysis. Infect Dis. 2019. 51(9): p. 639-650.
[16] Pázmány P, Soós A, Hegyi P, et al. Inflammatory biomarkers are inaccurate indicators of bacterial infection on admission in patients with acute exacerbation of chronic obstructive pulmonary disease-a systematic review and diagnostic accuracy network meta-analysis. Front Med (Lausanne), 2021. 8: p. 639794.
[17] Tanrıverdi H, Örnek T, Erboy F, et al. Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD. Wien Klin Wochenschr, 2015. 127(19-20): p. 756-63.

Downloads: 25
Visits: 1679

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.